Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice
- 1 August 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 11 (7) , 579-582
- https://doi.org/10.1097/00001813-200008000-00010
Abstract
This study was designed to asses the inhibition of tumor growth by oxaliplatin combined with UFT and folinic acid (FA). Growth inhibition was studied in nude mice transplanted with human colorectal HT29 tumor cell xenografts and treated for 28 days with oral UFT (20 mg/kg/day) and FA (4 mg/kg/day), i.p. oxaliplatin (10 mg/kg on day 1) or a combination of oxaliplatin, UFT and FA, or else not treated (controls). Tumor surface area and weight were recorded twice a week, and mice were sacrificed at day 28. Two separate experiments were performed for each group of 25 mice. At day 28, mean tumor weights (g) were 2.89±0.22 (controls), 2.03±0.14 (oxaliplatin), 2.02±0.21 (UFT/FA) and 1.23±0.17 (oxaliplatin+UFT/FA). For the three treatment groups, tumor weight decreases were 30.1% (ppKeywords
This publication has 4 references indexed in Scilit:
- Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancersAnti-Cancer Drugs, 1997
- Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancerEuropean Journal Of Cancer, 1997
- Mechanism–Based Improvement in the Therapeutic Selectivity of 5-FU Prodrug Alone and Under Conditions of Metabolic ModulationOncology, 1997
- Phase II trial of UFT in advanced colorectal and gastric cancerBritish Journal of Cancer, 1990